

Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday 3 October 2018, from 10am to 5.30pm

Venue: 10 Spring Gardens
London
SW1A 2BU

Present:	1. Dr Amanda Adler (Chair)	Present for all notes
	2. Dr Sanjeev Patel (Vice-Chair and Chair for notes)	Present for all notes
	3. Dr Carlo Berti	Present for all notes
	4. Professor John Cairns	Present for all notes
	5. Mr Mark Chapman	Present for all notes
	6. Ms Susan Faulds	Present for all notes
	7. Dr Mark Glover	Present for all notes
	8. Mr Richard Hoddes	Present for all notes
	9. Dr Mona Johnson	Present for all notes
	10. Dr Sanjay Kinra	Present for all notes
	11. Dr Nicholas Latimer	Present for all notes
	12. Mr Christopher O'Regan	Present for all notes
	13. Professor Stephen Palmer	Present for all notes
	14. Professor Allyson Pollock	Present for notes 11 to 42
	15. Mr William Turner	Present for all notes
	16. Professor Nicky Welton	Present for all notes
	17. Mr Nigel Westwood	Present for notes 11 to 42
	18. Dr Stuart Williams	Present for all notes

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Dr Melinda Goodall	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Jeremy Powell	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Sandra Aleknavice	Administrator, National Institute for Health and Care Excellence	Present for all notes

Dr Mary Hughes	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 16
Ross Dent	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 1 to 28
Jessica Cronshaw	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 28
Dr Sharlene Ting	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 29 to 42
Jamie Elvidge	Technical Adviser, National Institute for Health and Clinical Excellence	Present for notes 29 to 42
Professor Matthew Stevenson	Professor of Health Technology Assessment, School of Health and Related Research (SchARR)	Present for notes 1 to 13
Professor Sunil Bhandri	Consultant Nephrologist Hull and East Yorkshire Hospitals NHS Trust, clinical expert, nominated by the UK Renal Association	Present for notes 5 to 14 and for notes 17 to 26
Mr Nick Hartshorne- Evans	Patient expert, nominated by the Pumping Marvellous Foundation	Present for notes 5 to 14 and for notes 17 to 26
Mrs Fiona Loud	Patient expert, nominated by Kidney Care UK	Present for notes 5 to 14 and for notes 17 to 26
Hayley Wells	Principal transplant, renal and urology pharmacist, Guy's and St. Thomas NHS Foundation Trust, clinical expert, nominated by the UK Renal Pharmacy Group	Present for notes 17 to 26
Becky Pennington	Research Fellow, Decision Support Unit	Present for notes 29 to 39
Dr Jonathan Hind	Consultant in Paediatric Hepatology, Kings College Hospital, clinical expert nominated by	Present for notes 29 to 37

Professor Simon Lal	Shire Professor of Gastroenterology, Salford Royal Foundation Trust, clinical expert nominated by Shire	Present for notes 29 to 37
Dr Farooq Rahman	Consultant Gastroenterologist, University College London Hospitals, clinical expert nominated by Shire	Present for notes 29 to 37

Non-public attendees:

Helen Barnett	Medical Editor, NICE	Present for all notes
Edgar Masanga	Business Analyst, NICE	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293], patiomer for treating hyperkalaemia [ID877] and teduglutide for treating short bowel syndrome [ID885].
2. The Chair informed the Committee of the non-public observers at this meeting: Helen Barnett and Edgar Masanga.
3. Apologies were received from Mr Diar Fattah, Dr Stephen Smith and Professor Sarah Wild.

Any other Business

4. The Committee were given an update on the progress and timelines for other appraisals they have considered at previous meetings.

Appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293]

Part 1 – Open session

5. The Chair welcomed the invited experts: Professor Matthew Stevenson, Professor Sunil Bhandri, Mr Nick Hartshorne-Evans and Mrs Fiona Loud to the meeting and they introduced themselves to the Committee.
6. The Chair welcomed company representatives from AstraZeneca to the meeting.
7. The Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Stephen Palmer, Professor

Allyson Pollock, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].

8. The Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
9. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 9.1. Professor Matthew Stevenson, Mr Nick Hartshorne-Evans and Mrs Fiona Loud declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
 - 9.2. Professor Sunil Bhandri declared a personal specific non-financial interest as he is an investigator on a trial funded by AstraZeneca.
 - 9.2.1. It was agreed that this declaration would not prevent Professor Bhandri from participating in this section of the meeting
10. The Chair introduced the lead team, Dr Mona Johnson and Mr Chris O'Regan who gave presentations on the clinical effectiveness and cost effectiveness of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
11. Professor Allyson Pollock and Mr Nigel Westwood arrived and stated that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
12. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
13. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

14. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

15. Discussion on confidential information continued. This information was supplied by the company.
16. The Committee continued to discuss the clinical and cost effectiveness of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
 - 16.1. The committee decision was based on consensus.
17. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of patiromer for treating hyperkalaemia [ID877]

Part 1 – Open session

18. The Chair welcomed the invited experts: Dr Lena Al-Khudairy, Dr Ewen Cummins, Prof James Mason, Professor Sunil Bhandri, Ms Hayley Wells, Mr Nick Hartshorne-Evans and Mrs Fiona Loud to the meeting and they introduced themselves to the Committee.
19. The Chair welcomed company representatives from Vifor to the meeting.
20. The Chair asked all Committee members to declare any relevant interests
 - 20.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Stephen Palmer, Professor Allyson Pollock, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of patiromer for treating hyperkalaemia [ID877].
21. The Chair asked all NICE Staff to declare any relevant interests.
 - 21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of patiromer for treating hyperkalaemia [ID877].
22. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 22.1. Dr Lena Al-Khudairy, Dr Ewen Cummins, Prof James Mason, Ms Hayley Wells, Mr Nick Hartshorne-Evans and Mrs Fiona Loud declared that they

knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of patiommer for treating hyperkalaemia [ID877].

- 22.2. Professor Sunil Bhandri declared a personal specific non-financial interest as he is an investigator on a trial funded by AstraZeneca.
 - 22.2.1. It was agreed that this declaration would not prevent Professor Bhandri from participating in this section of the meeting
23. The Chair introduced the lead team, Dr Mona Johnson, Mr Chris O'Regan and Mr Nigel Westwood, who gave presentations on the clinical effectiveness and cost effectiveness of patiommer for treating hyperkalaemia [ID877].
24. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
25. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
26. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

27. Discussion on confidential information continued. This information was supplied by the company.
28. The Committee continued to discuss the clinical and cost effectiveness of patiommer for treating hyperkalaemia [ID877].
 - 28.1. The committee decision was based on consensus.
29. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of teduglutide for treating short bowel syndrome [ID885]

Part 1 – Open session

30. The Chair welcomed the invited experts: Becky Pennington, Dr Jonathan Hind, Professor Simon Lal and Dr Farooq Rahman to the meeting and they introduced themselves to the Committee.
31. The Chair welcomed company representatives from Shire to the meeting.
32. The Chair asked all Committee members to declare any relevant interests
 - 32.1. Dr Amanda Adler, Dr Sanjeev Patel, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Ms Susan Faulds, Dr Mark Glover, Mr Richard Hoddes, Dr Mona Johnson, Dr Sanjay Kinra, Dr Nicholas

Latimer, Mr Christopher O'Regan, Professor Stephen Palmer, Professor Allyson Pollock, Mr William Turner, Professor Nicky Welton, Mr Nigel Westwood and Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of teduglutide for treating short bowel syndrome [ID885].

33. The Chair asked all NICE Staff to declare any relevant interests.
 - 33.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of teduglutide for treating short bowel syndrome [ID885].
34. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.
 - 34.1. Becky Pennington declared that she knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of teduglutide for treating short bowel syndrome [ID885].
 - 34.2. Dr Jonathan Hind declared a personal specific financial interest as he has served on an advisory board for Shire and received funding to attend a conference.
 - 34.2.1. It was agreed that this declaration would not prevent Dr Hind from participating in this section of the meeting
 - 34.3. Professor Simon Lal declared a personal specific financial interest as he has received honoraria and funding for attending conferences from Shire. His department also receives support for research from Shire.
 - 34.3.1. It was agreed that this declaration would not prevent Professor Lal from participating in this section of the meeting
 - 34.4. Dr Farooq Rahman declared a personal specific financial interest as he has received honoraria for attending advisory boards and funding for attending conferences from Shire. His department also receives support for research from Shire.
 - 34.4.1. It was agreed that this declaration would not prevent Dr Rahman from participating in this section of the meeting
35. The Chair introduced the key themes arising from the report from the Decision Support Unit and the responses to the consultation on that report.
36. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
37. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the

confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

38. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

39. Discussion on confidential information continued. This information was supplied by the company.
40. The Chair then thanked the Decision Support Unit representative for their attendance, participation and contribution to the appraisal and they left the meeting.
41. The Committee continued to discuss the clinical and cost effectiveness of teduglutide for treating short bowel syndrome [ID885].
 - 41.1. The committee decision was based on consensus.
42. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

43. Tuesday 6 November 2018 at 10 Spring Gardens, London SW1A 2BU